|
Mar 16
|
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
|
|
Mar 15
|
Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss
|
|
Mar 15
|
Q4 2023 Allogene Therapeutics Inc Earnings Call
|
|
Mar 14
|
Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ...
|
|
Mar 14
|
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 14
|
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
|
|
Mar 13
|
Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
|
|
Mar 12
|
Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease
|
|
Mar 12
|
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
|
|
Mar 5
|
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross
|
|
Mar 5
|
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
|
|
Jan 16
|
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
|
|
Jan 12
|
How Allogene (ALLO) Stock Stands Out in a Strong Industry
|
|
Dec 28
|
The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics
|
|
Dec 27
|
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
|
|
Dec 21
|
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
|
|
Dec 9
|
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
|
|
Dec 1
|
Allogene Therapeutics Announces Participation in December Investor Conference
|
|
Nov 8
|
Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues
|
|
Nov 3
|
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2023 Earnings Call Transcript
|